Clinical trials: Clinically Isolated Syndrome (CIS)
Relapsing-Remitting Multiple Sclerosis
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
This is a 1 year study to evaluate the efficacy, safety, and tolerability of Tovaxin T cell therapy in subjects with a clinically isolated syndrome (CIS) and relapse-remitting multiple sclerosis (RR-MS).
- Trial name
- TERMS (NCT00245622)
- Testing
- Tovaxin Autologous T cell vaccine
- Where
- 33 sites in United States
- Volunteers
- 150 people
- Sponsor
- Opexa Therapeutics, Inc.
Clinically Isolated Syndrome (CIS), Multiple Sclerosis (MS)
Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
This a retrospective, blinded trial in which collaborators in Italy will review the doppler findings from the Combined Transcranial and Extracranial Venous Doppler (CTEVD) trial in an attempt to measure reproducibility.
- Conditions
- Clinically Isolated Syndrome (CIS), Multiple Sclerosis (MS), Other Neurological Disorders (OND), Healthy (HC)
- Trial name
- NCT02308579
- Volunteers
- 499 people
- Sponsor
- University at Buffalo
Clinically Isolated Syndrome, Multiple Sclerosis
Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)
The purpose of this study is to develop tools to detect, measure, monitor and predict axonal damage in the course of CIS and during Multiple sclerosis (MS), in order to be able to consider as early as possible an adaptation of…
- Trial name
- cinocis (NCT03541226)
- Where
- France
- Volunteers
- 134 people
- Sponsor
- University Hospital, Lille
Multiple Sclerosis (MS), Clinically Isolated Syndrome (CIS)
Pregnancy Cohort in Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system frequently affecting females in their reproductive phase of life.
- Trial name
- NCT05010902
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Positron-Emission Tomography, Multiple Sclerosis
Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8101 for investigation in patients with Multiple Sclerosis compared to healthy volunteers
- Trial name
- NCT01031199
- Testing
- F-18 FEDAA1106 (BAY85-8101)
- Where
- 2 sites in Australia, Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
The primary objective is to assess the effect of treatment with glatiramer acetate (GA) compared to placebo on the time to conversion to CDMS, as determined by Poser criteria (the occurrence of the second clinical attack) during…
- Trial name
- PreCISe (NCT00666224)
- Testing
- Glatiramer Acetate (DB), Glatiramer Acetate (OL)
- Volunteers
- 481 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Prebiotic vs Probiotic in Multiple Sclerosis
This is a randomized crossover-designed study to explore the immunologic effects of Prebiotics, as opposed to direct supplementation with beneficial bacteria (Probiotics) in the immune system of patients with MS and Clinically…
- Trial name
- MS (NCT04038541)
- Testing
- Prebiotics (Prebiotin Prebiotic Fiber Stick Pac), Probiotics (Visbiome®)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Columbia University
Multiple Sclerosis
Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome
The main objective of this study is to evaluate the efficacy and tolerance of 2 years of treatment with cholecalciferol (vitamin D3) in patients with a clinically isolated syndrome at high risk for MS (CIS).
- Trial name
- D-Lay-MS (NCT01817166)
- Testing
- Vitamin D, Imaging, Lumbar puncture
- Where
- 33 sites in France, Martinique
- Volunteers
- 316 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis, Clinically Isolated Syndrome
Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System
The Multiple Sclerosis Functional Composite (MSFC), a reliable and well-validated instrument, was developed as a multidimensional quantitative measure of neurologic disability in MS.
- Trial name
- MSPT (NCT04599023)
- Testing
- MSPT
- Where
- Switzerland
- Volunteers
- 182 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Sclerosis (MS), Clinically Isolated Syndrome (CIS)
Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study
The aim of this prospective non-interventional neuropsychological one visit study involving functional MRI (fMRI) is to ascertain emotional processing in patients with Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS)…
- Trial name
- NCT02695394
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis, Clinically Isolated Syndrome
AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS
The definition of the most 'at-risk' population within highly susceptible groups would provide an opportunity for preemptive therapeutics.
- Trial name
- ARMS (NCT00617383)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Sclerosis, MS, Clinically Isolated Syndrome
Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis
A majority of patients with multiple sclerosis initially presents with a single demyelinating event, e.g. in the optic nerves, brain, brainstem or spinal cord, referred to as a clinically isolated syndrome (CIS).
- Trial name
- CIS-COHORT (NCT01371071)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Multiple Sclerosis
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.
- Trial name
- ENCORE (NCT01167426)
- Testing
- Glatiramer Acetate 20 mg/0.5 mL
- Volunteers
- 148 people
- Sponsor
- Teva Neuroscience, Inc.
Clinically Isolated Syndrome
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) …
- Trial name
- CIS-ON (NCT00287079)
- Testing
- Rebif®, No Treatment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (CIS) or…
- Trial name
- PROCEED (NCT02254304)
- Testing
- Rebif
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Oral Cladribine in Early Multiple Sclerosis (MS)
A randomized, double-blind, clinical trial to assess the safety and efficacy of two doses of oral cladribine versus placebo in participants who had a first clinical demyelinating event (clinically isolated syndrome).
- Trial name
- ORACLE MS (NCT00725985)
- Testing
- Cladribine, Rebif® new formulation (RNF)
- Where
- 158 sites in United States, Argentina and 32 more
- Volunteers
- 617 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
This is a study in patients with clinically isolated syndrome (CIS) and early relapsing remitting multiple sclerosis (RRMS) to assess the effects of glatiramer acetate (GA) subcutaneously on the condition of the optical nerve in…
- Trial name
- OCTIMS (NCT00910598)
- Testing
- glatiramer acetate
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Amphia Hospital
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)
The goal of this observational study is to learn about the role of kappa free light chains (KFLC) in cerebrospinal fluid (CSF) in the diagnosis of multiple sclerosis (MS) and clinically isolated syndrome (CIS).
- Trial name
- PRO-KFLC (NCT07183020)
- Testing
- Oligoclonal bands and kappa free light chains (KFLC)
- Where
- Germany
- Volunteers
- 1,142 people
- Sponsor
- Skripuletz, Thomas Prof. Dr.
Optic Neuritis, Multiple Sclerosis
The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CIS
Disruption of the blood brain barrier (BBB) is associated with inflammatory conditions of the central nervous system (CNS). This clinical trial aims to investigate whether following a gluten-free diet (GFD) for six months can…
- Conditions
- Optic Neuritis, Multiple Sclerosis, Clinically Isolated Syndrome
- Trial name
- NCT03451955
- Testing
- Gluten-free diet
- Where
- 2 sites in Denmark
- Volunteers
- 103 people
- Sponsor
- University of Copenhagen